Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Sarcoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

SORAVE

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

BATTLE Program: Sorafenib in Patients With NSCLC

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

PECASO

Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer